How Pfizer Makes its Money: Revenue Breakdown (2024)

How Does Pfizer Make its Money?

Pfizer Inc. (NYSE: PFE) generated $58.5 billion in revenue in fiscal year 2024 — flat year-over-year from $58.5B in 2023 — but the identical top-line number conceals a dramatic internal transformation: COVID product revenue fell by approximately $4B as the pandemic demand era ended, while oncology revenue surged by approximately $6B driven by the December 2023 completion of the $43 billion acquisition of Seagen, the world’s leading antibody-drug conjugate (ADC) oncology company. Pfizer is the world’s fourth-largest pharmaceutical company by revenue (behind Johnson & Johnson, Roche, and AbbVie depending on year) and operates across internal medicine, oncology, vaccines, and hospital products in over 180 countries.

Pfizer’s fundamental economic model is patent-protected pharmaceutical pricing: the company invests billions in R&D to discover or in-license new drug molecules, navigates 10–15 years of clinical trials and FDA approval processes, then monetizes successful approvals through a temporary monopoly period (typically 10–15 years of effective market exclusivity after approval, which accounts for years of patent life consumed during clinical development). During the exclusivity window, Pfizer prices drugs at significant premiums to manufacturing cost — generating gross margins of 60–75% on successful products — which funds ongoing R&D and generates substantial profits. When exclusivity expires, generic manufacturers enter, prices drop 80–90% within months, and the branded revenue disappears nearly entirely. This pattern — called the patent cliff — is Pfizer’s defining financial challenge over 2025–2030.

The COVID years (2021–2022) were transformational but distorting: Comirnaty (COVID vaccine) and Paxlovid (COVID antiviral) generated a combined $56.7B in revenue in 2022 alone — more revenue from two products in one year than Pfizer’s entire pre-pandemic annual revenue. This windfall was not reinvested in operations at scale; Pfizer used the capital to fund the Seagen acquisition ($43B) and maintain an elevated dividend. The COVID revenue reset — from $56.7B combined in 2022 to approximately $8.6B combined in 2024 — represents one of the fastest revenue-to-decline cycles in pharmaceutical history, and managing this transition while simultaneously integrating Seagen and facing the Eliquis patent cliff is the defining strategic challenge of Pfizer’s 2024–2028 period.

Key Takeaways

• $58.5B revenue in 2024 (+0% YoY) — deceptively flat; ex-COVID (removing Comirnaty and Paxlovid), Pfizer’s core business grew approximately +12% YoY, driven by Seagen oncology products, Vyndaqel growth, and Prevnar stability; the COVID headwind masked genuine operational progress in the underlying diversified pharmaceutical business
• The Seagen acquisition ($43B) is the defining strategic bet — Pfizer paid the largest pharmaceutical acquisition price in history for Seagen’s antibody-drug conjugate (ADC) technology platform; ADCs are a class of oncology drugs that function as “guided missiles” — attaching a cytotoxic (cell-killing) payload to an antibody that targets cancer-specific proteins, delivering chemotherapy directly to cancer cells while sparing healthy tissue; ADC technology is considered by oncologists to be one of the most important therapeutic advances in cancer treatment in 30 years; Seagen’s four approved products (Padcev, Adcetris, Tukysa, Tivdak) and deep ADC pipeline give Pfizer a 5–10 year head start in a category where competitors are scrambling to build or buy capability
• Oncology is now ~16% of revenue and the fastest-growing segment — growing from $3.7B in 2023 to $9.5B in 2024 (+157%), primarily from Seagen products in the post-acquisition period; Pfizer’s stated ambition is $25B+ in oncology revenue by 2030 — which would require roughly tripling from the current base and would make oncology ~35–40% of a hypothetically $65–70B revenue company; achieving this requires both existing product growth (Padcev, Adcetris expanding to new cancer indications) and pipeline success (dozens of ADC programs in clinical development)
• The patent cliff is existential — Pfizer faces patent expirations on products representing approximately $17–18B in annual revenue between 2025 and 2030: Eliquis (~$6.4B, patent expiration 2026–2028 in US), Prevnar 20 (~$6B, facing competition), Ibrance (~$5B breast cancer drug, biosimilar risk), and others; when a branded drug faces generic competition, revenue typically falls 70–90% within 12 months; unlike Eli Lilly or Novo Nordisk which are growing into patent cliff headwinds with GLP-1 blockbusters, Pfizer must replace cliff revenue primarily through pipeline launches and the Seagen portfolio — a more uncertain path
• COVID products ($8.6B) are stabilizing toward a durable base — Paxlovid rebounded sharply in 2024 (+146% to $3.2B) as the US government resumed purchasing and international markets expanded adoption; Comirnaty fell -52% to $5.4B as booster uptake normalized; the multi-year question is whether COVID vaccines/antivirals become a $5–8B annual recurring market similar to the influenza franchise (Pfizer’s flu vaccine Prevnar analog) or continue declining; current evidence suggests $5–7B is a reasonable steady-state for combined COVID products, representing durable rather than disappearing revenue
• Net income returned to positive in 2024 ($8.0B) — after a -$2.1B net loss in 2023 driven by massive COVID inventory write-downs ($5.6B) and Seagen acquisition costs; the 2024 recovery to $8.0B net income (13.7% net margin) reflects: elimination of the inventory write-down charges, improved product mix (lower-cost COVID product sales as commercial inventory was drawn down), and operational cost reductions under the “Pfizer Flex” cost reduction program targeting $4B in annual savings by end of 2025
• Vyndaqel ($4.1B, +24.2%) is Pfizer’s most underappreciated growth asset — treatment for transthyretin amyloid cardiomyopathy (ATTR-CM), a previously underdiagnosed fatal heart disease where misfolded proteins deposit in the heart; as ATTR-CM diagnosis rates improve (better diagnostic imaging, increased physician awareness) and Vyndaqel’s benefit becomes more established in cardiology practice, patient volumes should grow substantially; Pfizer’s internal estimates suggest the diagnosable ATTR-CM population is 5–10x the currently treated population, implying significant long-term revenue upside from diagnosis penetration alone

Pfizer (PFE) Business Model

Pfizer operates through the classic patent-protected pharmaceutical business model — similar to Eli Lilly, Merck, and Johnson & Johnson — where sustainable value creation requires continuously replenishing a pipeline of new drug approvals to offset revenue lost when patents expire.

The drug economics lifecycle:

The average drug that eventually reaches market took approximately 12 years and $2.6 billion (including the cost of failed programs) to develop. Pfizer’s $10–11B annual R&D budget funds approximately 100 clinical programs simultaneously, of which historically 5–10 will reach approval per decade. Each successful approval must generate enough revenue to cover the cost of both itself and the 95% of programs that failed.

Three revenue model types within Pfizer:

1. Small molecule drugs (most of Pfizer’s portfolio): Chemical compounds manufactured at relatively low cost but sold at substantial premiums due to patent protection; once off-patent, generic manufacturers replicate the chemical formula cheaply; examples: Eliquis, Ibrance, Vyndaqel, legacy antibiotic portfolio

2. Biologics and vaccines (higher barrier to generic competition): Large protein molecules (biologics) or killed/attenuated virus preparations (vaccines) that are more complex to manufacture than small molecules; “biosimilar” versions can enter the market after patent expiry, but the regulatory pathway is more burdensome than generic small molecule approval, and biosimilars typically capture less market share; examples: Comirnaty, Prevnar 20, Enbrel (in US)

3. Antibody-drug conjugates (ADCs via Seagen): The most complex and expensive to manufacture; ADCs consist of a monoclonal antibody (targeting cancer cells), a chemical linker, and a cytotoxic payload; the manufacturing process is highly specialized and even post-patent, ADC biosimilars face significant technical barriers to entry; examples: Padcev, Adcetris, Tivdak; ADC manufacturing complexity provides more durable revenue than small molecule drugs after patent expiry — a key reason Pfizer paid $43B for Seagen

Why the patent cliff is structurally different from revenue cyclicality: Unlike Home Depot facing a housing market downturn or Goldman Sachs in a low-deal-volume year, Pfizer’s patent cliff is a known, scheduled, and irreversible revenue event. The only responses are: (1) pipeline success (internally discovered new drugs), (2) business development (acquisitions like Seagen), (3) cost reduction (Pfizer Flex), or (4) accepting a structurally smaller company. Pfizer is executing all four simultaneously.

Pfizer Competitors

Large diversified pharma:

• Johnson & Johnson — Pfizer’s closest peer in scale and diversification; J&J spun off its consumer health division (now Kenvue) in 2023, focusing entirely on pharmaceutical and MedTech; J&J’s oncology portfolio (Darzalex for multiple myeloma, Imbruvica for blood cancers) competes directly with Pfizer’s oncology ambitions; J&J generated approximately $88B in total revenue in 2024 — making it roughly 50% larger than Pfizer by revenue; J&J’s advantage over Pfizer: less exposure to the dramatic COVID revenue cliff and a more evenly distributed portfolio across therapeutic areas
• Merck — Merck’s Keytruda (pembrolizumab), a PD-1 checkpoint inhibitor approved across 40+ cancer indications, generated approximately $25B in 2024 revenue — making it the world’s best-selling drug; Keytruda is the dominant oncology immunotherapy and competes with Pfizer’s ADC portfolio for oncology market share (oncologists choose between checkpoint inhibitors, ADCs, or combinations for each patient); Merck also has Gardasil (HPV vaccine, ~$9B revenue) competing with Pfizer’s Prevnar in the vaccine market
• Eli Lilly — Eli Lilly’s GLP-1 portfolio (Mounjaro/Zepbound for diabetes/obesity) is growing at $20B+ annually and represents the most powerful pharmaceutical franchise in decades; Pfizer is developing its own oral GLP-1 candidate (danuglipron) to compete in this category, but Lilly and Novo Nordisk have 5–7 year head starts with established products, manufacturing capacity, and physician prescribing habits; see Eli Lilly vs Novo Nordisk for GLP-1 competitive dynamics

Oncology ADC competitors:

• AstraZeneca/Daiichi Sankyo: AstraZeneca in-licensed multiple ADC programs from Daiichi Sankyo (including Enhertu, the leading HER2-targeted ADC for breast cancer) and is the primary ADC competitor to Seagen/Pfizer; AstraZeneca’s ADC pipeline is considered as deep as Seagen’s; the two companies are competing in the same cancer indications
• AbbVie: AbbVie acquired ImmunoGen (an ADC pioneer) for $10.1B in 2024 specifically to compete in the ADC space against Pfizer/Seagen

COVID vaccine competition:

• Moderna — Moderna’s mRNA COVID vaccine (Spikevax) competes directly with Pfizer/BioNTech’s Comirnaty; in 2024, Comirnaty maintained significantly higher market share in the US and globally; Moderna has faced more commercial challenges adapting to the post-pandemic environment but retains its mRNA technology advantage

For pharmaceutical distribution context, see Walgreens vs CVS — the two largest pharmacy chains are key distribution partners and pricing negotiators for Pfizer’s retail products.

Revenue Breakdown

Financial data sourced from Pfizer 2024 Annual Report (10-K). Product-level figures are rounded estimates based on disclosed segment data.

Oncology Deep-Dive — Seagen ADC Platform

Padcev (enfortumab vedotin) — a bladder cancer ADC targeting Nectin-4, a protein overexpressed in urothelial (bladder/urinary tract) cancers; Padcev in combination with Keytruda (Merck’s checkpoint inhibitor) became the standard of care for first-line metastatic urothelial cancer in 2024 based on clinical trial results showing dramatically improved survival; revenue surging from $0.3B pre-acquisition to $2.6B in 2024 as the combination is adopted globally; peak sales estimates of $6–8B make Padcev potentially Pfizer’s third-largest product within 3 years

Adcetris (brentuximab vedotin) — an ADC targeting CD30, a protein expressed on certain lymphoma cells; approved for Hodgkin lymphoma and certain T-cell lymphomas; one of the first commercially successful ADCs (approved 2011 before Seagen was acquired); generates approximately $1.4B in revenue with modest growth as the drug is well-established in its approved indications; new combination studies could expand the addressable market

Ibrance (palbociclib) — a CDK4/6 inhibitor for HR+/HER2- breast cancer (Pfizer’s largest oncology product before Seagen); Ibrance revenue declining -10.2% as biosimilar competition emerges and Eli Lilly’s Verzenio (abemaciclib, a competing CDK4/6 inhibitor with slightly different profile) gains market share; Ibrance generated $4.4B in 2024 and faces continued revenue pressure through 2027 as generics erode market share

Vyndaqel — The Underappreciated Growth Driver

Vyndaqel (tafamidis) treats transthyretin amyloid cardiomyopathy (ATTR-CM) — a fatal heart disease where a protein called transthyretin misfolds and deposits in the heart muscle, progressively impairing cardiac function. ATTR-CM was almost entirely undiagnosed before 2019 (misdiagnosed as heart failure) because the diagnostic tools (nuclear imaging scans) were not widely used in cardiology. Vyndaqel stabilizes the transthyretin protein, reducing deposit formation and slowing disease progression — the only approved treatment until BridgeBio’s acoramidis (approved late 2023) created the first real competition.

The market expansion opportunity: cardiologists estimate 100,000–400,000 US patients have ATTR-CM, of whom only approximately 30,000–50,000 are currently diagnosed and treated with tafamidis. As cardiac nuclear imaging (pyrophosphate scan) becomes more routinely ordered and physician awareness grows, the diagnosed population should expand dramatically. At approximately $225,000/year per patient in the US, each 10,000 additional patients diagnosed represents approximately $2.25B in additional annual US revenue potential. BridgeBio’s acoramidis (Attruby) is a competing stabilizer with some clinical differentiation that will take modest market share, but the diagnosis penetration tailwind benefits both products.

Eliquis — The Looming $6B Patent Cliff

Eliquis (apixaban) is a direct oral anticoagulant (blood thinner) that Pfizer co-promotes and co-profits with Bristol-Myers Squibb. Eliquis prevents blood clots in patients with atrial fibrillation, deep vein thrombosis, and pulmonary embolism — massive, chronic disease populations requiring lifetime treatment. Global Eliquis sales were approximately $12B in 2024, with Pfizer recording ~$6.4B (its share of the collaboration profit, not the full revenue).

The patent cliff risk: Eliquis patents expire in the US in approximately 2026–2028 depending on the specific patent (there is active litigation with generic manufacturers challenging patent validity). Once generics enter, Eliquis revenue to Pfizer will fall 70–90% within 24 months — a potential $5–6B annual revenue loss. This is the most significant single patent cliff event on Pfizer’s horizon. Replacing $6B in high-margin Eliquis revenue requires approximately $8–10B in new product revenue at lower margins, or 3–4 new blockbuster drug approvals — making pipeline execution critical.

Revenue Trend (3-Year)

The ex-COVID trajectory (bottom two columns) tells the real story: Pfizer’s non-COVID business has grown from $43.6B (2022) → $46.0B (2023) → $49.9B (2024) — compound growth of approximately +7% over two years, ahead of industry average. The pandemic revenue spike ($100.3B in 2022) and collapse ($58.5B in 2023 and 2024) created a misleading narrative of a company in freefall when the underlying diversified business was modestly growing throughout.

Pfizer (PFE) Income Statement

Gross margin recovery to 62.1% (+600bps) — driven by the elimination of approximately $5.6B in COVID inventory write-downs that distorted 2023 cost of sales; 2023 cost of sales was elevated because Pfizer wrote down billions in COVID vaccine and antiviral inventory that had been manufactured but could not be sold at contracted quantities as demand collapsed; 2024’s normalized 62.1% gross margin reflects the underlying product mix without one-time write-down effects.

Operating expense improvement (-24.3%) — reflects: (1) zero acquired in-process R&D charges in 2024 vs. $6.1B in 2023 (related to Seagen acquisition closing); (2) lower restructuring charges as Pfizer Flex cost program matures; (3) SG&A reduction of -7.0% reflecting headcount reductions and marketing spend optimization.

Diluted EPS of $1.41 — significantly lower than Pfizer’s pre-pandemic EPS (~$3.50–4.00) due to the COVID revenue reset, Seagen acquisition dilution, and elevated debt service costs; the gap between reported EPS ($1.41) and adjusted non-GAAP EPS (approximately $2.90–3.10) reflects significant amortization of Seagen intangibles, restructuring charges, and other items excluded from the adjusted figure.

Pfizer (PFE) Key Financial Metrics

• Gross Margin: 62.1% — in line with large-cap pharma peers (J&J ~68%, Eli Lilly ~81%, Merck ~75%); Pfizer’s gross margin is somewhat below peers because its portfolio includes more commoditized hospital products (generic injectables, basic antibiotics) alongside the high-margin patent-protected portfolio; as oncology (particularly ADCs, which carry 65–75% gross margins) becomes a larger revenue share, gross margin should trend toward 65%+

• Operating Margin: 17.4% — recovering from the distorted 2023 figure; Pfizer’s normalized operating margin excluding one-time charges and Seagen amortization is approximately 22–25%; achieving sustained 20%+ reported operating margin requires: revenue growth from Seagen oncology products, cost reduction program completion, and Eliquis revenue holding before patent cliff

• Free Cash Flow: Pfizer generated approximately $8–10B in operating cash flow in 2024 (lower than historical norms due to Seagen integration costs and Paxlovid inventory drawdown); maintaining FCF at $8–10B annually supports: the $0.42/quarter dividend (approximately $5.8B annually, Pfizer’s highest priority capital use), debt service on Seagen acquisition financing (~$3B), and ongoing share repurchases when FCF allows

• Long-Term Debt: Approximately $62B following the Seagen acquisition financing; Pfizer has used its strong FCF history to access debt markets at attractive rates; however, the elevated debt load limits financial flexibility — particularly concerning if pipeline setbacks reduce revenue expectations; debt reduction is a secondary priority after the dividend but before share repurchases

• R&D intensity: ~18.8% of revenue — one of the highest R&D ratios in large-cap pharma (Eli Lilly invests 22%+, Merck ~18%, J&J ~15%); Pfizer’s $11B R&D budget supports ~100 clinical programs; the ROI on this investment is uncertain — historically, approximately 10% of Phase I drugs reach approval, rising to ~50% survival from Phase III; the Seagen acquisition effectively “bought” a large, de-risked late-stage ADC pipeline rather than building it from Phase I

Is Pfizer Profitable?

Yes. Pfizer reported net income of $8.0 billion in fiscal year 2024 — a dramatic recovery from the -$2.1 billion net loss in 2023, which was driven by non-recurring items (COVID inventory write-downs, acquired in-process R&D charges at Seagen closing). On an adjusted non-GAAP basis (which Pfizer uses in management guidance and which excludes amortization of Seagen intangibles, restructuring, and other items), Pfizer’s adjusted net income was approximately $13–15B — more representative of the underlying cash-generating power of the business. The gap between GAAP ($8B) and adjusted ($13–15B) earnings is primarily the amortization of the $43B Seagen acquisition’s intangible assets, which will flow through the income statement over 15–20 years.

What to Watch

1. Eliquis patent cliff timeline and litigation outcome — Eliquis patent expiration (2026–2028 in the US) is the most significant known revenue event on Pfizer’s horizon; generic manufacturers have challenged Eliquis patents in court; if courts rule against Pfizer, generic entry could accelerate to 2026, triggering a $5–6B revenue loss earlier than modeled; watch quarterly litigation disclosures and any news of generic manufacturer ANDA (Abbreviated New Drug Application) approvals at FDA

2. Padcev and Adcetris commercial uptake — Pfizer needs its Seagen ADC products to reach $8–10B+ in combined annual revenue by 2028 to justify the $43B acquisition price; watch quarterly revenue disclosures for Padcev (bladder cancer, should be largest ADC product as first-line combination with Keytruda becomes standard of care globally) and Adcetris (lymphoma, more established market); the speed of international regulatory approvals and reimbursement decisions outside the US will determine whether peak estimates are achievable

3. Danuglipron (oral GLP-1) clinical data — if Pfizer’s once-daily obesity pill achieves Phase III efficacy comparable to Eli Lilly’s Zepbound or Novo Nordisk’s Wegovy, it would enter the largest potential drug market in history with a once-daily pill vs. weekly injectable advantage; however, Pfizer has already discontinued one GLP-1 candidate (twice-daily danuglipron) due to tolerability issues; the once-daily program is the last shot; clinical data readout in 2025–2026 is a binary event — success adds $10B+ revenue upside to long-term models, failure eliminates Pfizer from the obesity race entirely; see Eli Lilly vs Novo Nordisk for the market Pfizer is trying to enter

4. Pfizer Flex cost savings completion — Pfizer announced a $4B annual cost reduction target by end of 2025 through headcount reductions, real estate optimization, and operational efficiency; as of late 2024, approximately $3.5B in annualized savings had been achieved; completion of the full $4B savings provides a ~$500M operating income uplift in 2025 and helps offset revenue headwinds; watch SG&A and cost of goods trends in quarterly filings

5. Vyndaqel (ATTR-CM) market expansion — the 30,000–50,000 currently treated patients represent only 10–30% of the estimated diagnosable ATTR-CM population; as cardiac nuclear imaging protocols become standard in heart failure workups, the diagnosed population should expand substantially; watch quarterly Vyndaqel revenue growth rate — sustained 20%+ growth would confirm the diagnosis penetration thesis; BridgeBio’s Attruby (acoramidis) market share gains will be a partial offset but the market expansion story is more important than competition

6. Pipeline milestone events — Pfizer’s 2025–2027 pipeline has approximately 20 potential Phase III readouts and FDA filings across oncology, vaccines, and inflammation/immunology; each successful approval is worth an estimated $500M–5B in peak annual sales; each failure represents both a financial write-off and a missed revenue replacement opportunity; the aggregate pipeline success rate will determine whether Pfizer can navigate the 2026–2028 patent cliff period without a significant revenue decline

Pfizer (PFE) Financial Summary

Pfizer Inc. (NYSE: PFE) generated $58.5 billion in 2024 revenue (+0% YoY but +12% ex-COVID), earning $8.0 billion in net income (13.7% net margin) with a recovering 62.1% gross margin — restored from 2023’s distorted 56.1% after the elimination of COVID inventory write-downs. The defining strategic event was the integration of Seagen’s antibody-drug conjugate oncology platform (acquired for $43B in December 2023), which drove oncology revenue to $9.5B (+157% YoY) and positions Pfizer to target $25B+ in oncology revenue by 2030. The core investment thesis is a pipeline execution story: can Pfizer’s Seagen ADC portfolio (led by Padcev at $2.6B and growing), Vyndaqel ATTR-CM platform (+24% and underpenetrated), and potential GLP-1 entry offset the patent cliff headwinds from Eliquis (~$6B at risk 2026–2028), Ibrance erosion, and lingering COVID revenue normalization? The elevated $62B debt load from the Seagen acquisition limits financial flexibility and creates a high bar for pipeline success. See Eli Lilly vs Novo Nordisk for GLP-1 competition context and Walgreens vs CVS for pharmaceutical distribution dynamics. Full sector analysis: Healthcare Sector.